H.I.G. BioHealth Partners is the dedicated life-science investment affiliate of H.I.G. Capital, investing in a broad range of healthcare companies across sectors and stages of development, including therapeutic drugs, medical devices, diagnostics, and digital health.
60% of their portfolio is in Healthcare. Average disclosed round size is $83.4M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$400M
Top Stage
Unknown
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| OOn Target Laboratories | Series C | $30M | Nov 2023 |
 Click Therapeutics | Series B | $48.5M | Jan 2021 |
 Arvelle | Series A | $180M | Feb 2019 |
| Arvelle | Unknown | $207.8M | Jan 2019 |
 Intact Vascular | Series C | — | Jan 2019 |
 On Target Labs | Series B | $44M | Mar 2018 |
| Intact Vascular | Series B | $46M | Jan 2017 |
 Vertiflex, Inc. | Unknown | $40M | Jan 2017 |
 Arvelle Therapeutics | Unknown | — | — |
 Orbus Therapeutics | Series A | $71M | — |
Top Co-Investors
Andera Partners3 shared
EQT Life Sciences3 shared
NovaQuest Capital Management3 shared
BRV Capital Management3 shared
New Enterprise Associates3 shared
Elevate Ventures2 shared
F-Prime Capital2 shared
Sanofi Ventures1 shared
Accelmed Partners1 shared
Health Catalyst Capital1 shared
K2 HealthVentures1 shared
Revelation Partners1 shared
3B Future Health Fund1 shared
Olympus Innovation Ventures1 shared
Morgenthaler Ventures1 shared
Alta Partners1 shared
Endeavour Vision1 shared
Runway Growth Capital1 shared
Longitude Capital1 shared
Adams Street Partners1 shared
Last updated: 20 October 2026